GlassScriptPhysician profile
Kristopher S Pfirman
NPI 1306233804
$17,971.51
in general payments reported to CMS, 2019-2025
29 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,209 · 2020: $445 · 2021: $304 · 2022: $34.26 · 2023: $727 · 2024: $575 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $2,971 · Food and Beverage: $2,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,800.00 |
| Travel and Lodging | $2,971.14 |
| Food and Beverage | $2,207.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orapharma, A Division of Bausch Health US, LLC | $13,871.14 | 2025 | Arestin |
| Heartflow, INC. | $885.67 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $706.68 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $635.09 | 2019-2024 | Farxiga, Andexxa, Brilinta |
| Abiomed | $279.36 | 2019-2021 | |
| Amgen INC. | $209.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $195.79 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $158.79 | 2022-2023 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $122.16 | 2019-2023 | |
| Medtronic Vascular, INC. | $96.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $93.09 | 2019-2023 | Xarelto |
| Chiesi USA, INC. | $87.66 | 2019-2021 | |
| Zoll Circulation INC | $84.84 | 2023 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Amarin Pharma, INC. | $78.46 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $63.22 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $50.31 | 2019-2021 | |
| Philips North America LLC | $38.48 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $37.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.15 | 2020-2023 | Jardiance |
| Boston Scientific Corporation | $36.03 | 2020 | |
| Merck Sharp & Dohme LLC | $35.50 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $26.90 | 2021 | |
| Lundbeck LLC | $26.65 | 2019-2020 | |
| Esperion Therapeutics, INC. | $26.26 | 2020 | |
| Genzyme Corporation | $23.86 | 2023 | |
| Akcea Therapeutics, INC. | $23.49 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $17.03 | 2025 | Assure Wcd |
| Mallinckrodt Hospital Products INC. | $14.82 | 2021 | |
| Amryt Pharma Holdings LTD | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Pfirman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.